Homepage Top Section2

The cash-cum-stock deal between Takeda and Shire was signed in May 2018 in a move to create a global, values-based research and development (R&D) driven biopharma company headquartered

Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are

BioNTech has expanded its research collaboration with Sanofi formed in late 2015 to advance the development of mRNA-based cancer immunotherapies. Simultaneously, BioNTech has signed an agreement with Sanofi

The merger of Bristol-Myers Squibb and Celgene is expected to result in a specialty biopharma company that will strive to develop high-value innovative medicines to meet the needs

ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is

Antengene has secured the money under series B financing round led by Boyu Capital and FountainVest. The participants include new investors such as Celgene, WuXi Corporate Venture Fund

The vaccine, called Vaxelis, is indicated to prevent diphtheria, tetanus, poliomyelitis, pertussis, hepatitis B and invasive disease due to Haemophilus influenzae type b. It has been approved for

ACO is commonly associated with the ingestion of ‘edibles’ such as brownies, cookies and candies that contain large quantities of  D9-tetrahydrocannabinol (THC) and synthetic cannabinoids that are more

PCOS is the most common endocrine disorder found in reproductive-age women, and is a major cause of infertility and type 2 diabetes. The source of the disease is